4//SEC Filing
PHARMION CORP 4
Accession 0001209191-08-043754
CIK 0001203866operating
Filed
Jul 24, 8:00 PM ET
Accepted
Jul 25, 4:20 PM ET
Size
14.7 KB
Accession
0001209191-08-043754
Insider Transaction Report
Form 4
PHARMION CORPPHRM
McKinley Edward J
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2008-03-07−7,500→ 0 totalExercise: $18.65From: 2007-06-08Exp: 2016-06-07→ Common Stock (7,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2008-03-07−25,000→ 0 totalExercise: $48.26From: 2004-10-14Exp: 2014-10-14→ Common Stock (25,000 underlying) - Disposition to Issuer
Common Stock
2008-03-07−110,000→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2008-03-07−5,000→ 0 totalExercise: $20.33From: 2005-06-01Exp: 2015-06-01→ Common Stock (5,000 underlying)
Footnotes (5)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger, dated November 18, 2007, by and between Pharmion Corporation, Celgene Corporation and Cobalt Acquisition LLC in exchange for $25.00 and 0.8367 shares of common stock of Celgene Corporation having a market value of $47.49 on the effective date of the merger.
- [F2]These options were cancelled in the merger in exchange for $146,266.32 and 4,894 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.
- [F3]These options were cancelled in the merger in exchange for $62,972.94 and 2,107 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.
- [F4]These options were cancelled in the merger in exchange for $97,518.38 and 3,262 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.
- [F5]These options were cancelled in the merger in exchange for $74,683.90 and 2,497 shares of common stock of Celgene Corporation having a market value of $56.76 per share on the effective date of the merger, representing the merger consideration the Reporting Person would have received had the Reporting Person effected a cashless exercise of such options immediately prior to the closing of the merger.
Documents
Issuer
PHARMION CORP
CIK 0001203866
Entity typeoperating
Related Parties
1- filerCIK 0001203866
Filing Metadata
- Form type
- 4
- Filed
- Jul 24, 8:00 PM ET
- Accepted
- Jul 25, 4:20 PM ET
- Size
- 14.7 KB